Iron and steatohepatitis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue SUPPL.2, 2012, Pages 42-46

  Corradini, Elena ^a   Pietrangelo, Antonello ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Alcoholic liver disease; Fatty liver disease; Hepcidin; Iron; Steatohepatitis

Indexed keywords

ALCOHOL; CCAAT ENHANCER BINDING PROTEIN ALPHA; FERROPORTIN; HEPCIDIN; IRON; JANUS KINASE 2; MESSENGER RNA; STAT3 PROTEIN;

ALCOHOL LIVER DISEASE; ALCOHOLIC PANCREATITIS; CELL DEATH; DISEASE COURSE; ENDOPLASMIC RETICULUM STRESS; GENE MUTATION; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; IRON DEPLETION; KUPFFER CELL; LIVER CELL; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DNA BINDING; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

EID: 84856954278     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.07014.x     Document Type: Review

References (50)

1. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141(5): 1572-85.
2. Anstee QM, Daly AK, Day CP. Genetic modifiers of non-alcoholic fatty liver disease progression. Biochim. Biophys. Acta 2011; 1812: 1557-66.
3. Deugnier Y, Turlin B. Pathology of hepatic iron overload. Semin. Liver Dis. 2011; 31: 260-71.
4. Pietrangelo A. Iron in NASH, chronic liver diseases and HCC: how much iron is too much? J. Hepatol. 2009; 50: 249-51.
5. Pietrangelo A. Iron chelation beyond transfusion iron overload. Am. J. Hematol. 2007; 82: 1142-6.
6. Pietrangelo A. Metals, oxidative stress, and hepatic fibrogenesis. Semin. Liver Dis. 1996; 16: 13-30.
7. Pietrangelo A. Hepcidin in human iron disorders: therapeutic implications. J. Hepatol. 2011; 54: 173-81.
8. Corradini E, Meynard D, Wu Q etal. Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice. Hepatology 2011; 54: 273-84.
9. Vecchi C, Montosi G, Zhang K etal. ER stress controls iron metabolism through induction of hepcidin. Science 2009; 325: 877-80.
10. Nemeth E. Iron regulation and erythropoiesis. Curr. Opin. Hematol. 2008; 15: 169-75.
11. Friedman IM, Kraemer HC, Mendoza FS, Hammer LD. Elevated serum iron concentration in adolescent alcohol users. Am. J. Dis. Child. 1988; 142: 156-9.
12. Kohgo Y, Ohtake T, Ikuta K etal. Iron accumulation in alcoholic liver diseases. Alcohol. Clin. Exp. Res. 2005; 29: 189S-93S.
13. Duane P, Raja KB, Simpson RJ, Peters TJ. Intestinal iron absorption in chronic alcoholics. Alcohol Alcohol. 1992; 27: 539-44.
14. Ji C. Mechanisms of alcohol-induced endoplasmic reticulum stress and organ injuries. Biochem. Res. Int. 2012; 2012: 216450.
15. Harrison-Findik DD, Schafer D, Klein E etal. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J. Biol. Chem. 2006; 281: 22974-82.
16. Bridle K, Cheung TK, Murphy T etal. Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. Alcohol. Clin. Exp. Res. 2006; 30: 106-12.
17. Harrison-Findik DD, Klein E, Crist C, Evans J, Timchenko N, Gollan J. Iron-mediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol. Hepatology 2007; 46: 1979-85.
18. Ohtake T, Saito H, Hosoki Y etal. Hepcidin is down-regulated in alcohol loading. Alcohol. Clin. Exp. Res. 2007; 31 (Suppl.): S2-8.
19. Tsukamoto H, Lin M, Ohata M, Giulivi C, French SW, Brittenham G. Iron primes hepatic macrophages for NF-kappaB activation in alcoholic liver injury. Am. J. Physiol. 1999; 277 (Pt 1): G1240-50.
20. She H, Xiong S, Lin M, Zandi E, Giulivi C, Tsukamoto H. Iron activates NF-kappaB in Kupffer cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2002; 283: G719-26.
21. Ganne-Carrié N, Christidis C, Chastang C etal. Liver iron is predictive of death in alcoholic cirrhosis: a multivariate study of 229 consecutive patients with alcoholic and/or hepatitis C virus cirrhosis: a prospective follow up study. Gut 2000; 46: 277-82.
22. Nahon P, Sutton A, Rufat P etal. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology 2008; 134: 102-10.
23. Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DHG. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary HC: quantifying the risk. Gastroenterology 2002; 122: 281-9.
24. Chapman RW, Morgan MY, Laulicht M, Hoffbrand AV, Sherlock S. Hepatic iron stores and markers of iron overload in alcoholics and patients with idiopathic hemochromatosis. Dig. Dis. Sci. 1982; 27: 909-16.
25. Tavill AS, Qadri AM. Alcohol and iron. Semin. Liver Dis. 2004; 24: 317-25.
26. Pietrangelo A. Iron-induced oxidant stress in alcoholic liver fibrogenesis. Alcohol 2003; 30: 121-9.
27. Lin M, Rippe RA, Niemelä O, Brittenham G, Tsukamoto H. Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages. Am. J. Physiol. 1997; 272 (Pt 1): G1355.
28. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010; 51: 679-89.
29. Kotronen A, Juurinen L, Hakkarainen A etal. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 2008; 31: 165-9.
30. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332: 1519-23.
31. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J. Hepatol. 2009; 51: 371-9.
32. Day CP. From fat to inflammation. Gastroenterology 2006; 130: 207-10.
33. Moirand R, Mortaji AM, Loreal O, Paillard F, Brissot P, Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet 1997; 349: 95-7.
34. Mendler MH, Turlin B, Moirand R etal. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117: 1155-63.
35. Valenti L, Fracanzani AL, Bugianesi E etal. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2010; 138: 905-12.
36. Nelson JE, Wilson L, Brunt EM etal. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology 2011; 53: 448-57.
37. Fernández-Real JM, López-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 2002; 51: 2348-54.
38. Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J. Hepatol. 2011; 55: 920-32.
39. Bekri S, Gual P, Anty R etal. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 2006; 131: 788-96.
40. Chung B, Matak P, McKie AT, Sharp PJ. Leptin increases the expression of the iron regulatory hormone hepcidin in HuH7 human hepatoma cells. J. Nutr. 2007; 137: 2366-70.
41. Amato A, Santoro N, Calabrò P etal. Effect of body mass index reduction on serum hepcidin levels and iron status in obese children. Int. J. Obes. (Lond) 2010; 34: 1772-4.
42. Sorrentino P, D'Angelo S, Ferbo U, Micheli P, Bracigliano A, Vecchione R. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J. Hepatol. 2009; 50: 351-7.
43. Zimmermann A, Zimmermann T, Schattenberg J etal. Alterations in lipid, carbohydrate and iron metabolism in patients with non-alcoholic steatohepatitis (NASH) and metabolic syndrome. Eur. J. Intern. Med. 2011; 22: 305-10.
44. Nishina S, Hino K, Korenaga M etal. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 2008; 134: 226-38.
45. Valenti L, Dongiovanni P, Fracanzani AL etal. Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary HC. Dig. Liver Dis. 2003; 35: 172-8.
46. Kim JA, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circ. Res. 2008; 102: 401-14.
47. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 931-9.
48. Valenti L, Fracanzani AL, Dongiovanni P etal. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am. J. Gastroenterol. 2007; 102: 1251-8.
49. Bugianesi E, Manzini P, D'Antico S etal. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004; 39: 179-87.
50. Kowdley KV, Belt P, Wilson LA etal. for the NASH Clinical Research Network. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis among patients with nonalcoholic fatty liver disease. Hepatology 2012; 55(1): 77-85.